CN106687135A - 使用pd‑1轴结合拮抗剂和il‑17结合拮抗剂治疗癌症的方法 - Google Patents

使用pd‑1轴结合拮抗剂和il‑17结合拮抗剂治疗癌症的方法 Download PDF

Info

Publication number
CN106687135A
CN106687135A CN201580048941.5A CN201580048941A CN106687135A CN 106687135 A CN106687135 A CN 106687135A CN 201580048941 A CN201580048941 A CN 201580048941A CN 106687135 A CN106687135 A CN 106687135A
Authority
CN
China
Prior art keywords
binding antagonist
antibody
seq
cancer
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580048941.5A
Other languages
English (en)
Chinese (zh)
Inventor
J·格罗根
Y·肖
P·卡普拉斯
S·连诺格罗
J·哈克尼
E·Y-C·蒋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN106687135A publication Critical patent/CN106687135A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201580048941.5A 2014-09-15 2015-09-14 使用pd‑1轴结合拮抗剂和il‑17结合拮抗剂治疗癌症的方法 Pending CN106687135A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462050745P 2014-09-15 2014-09-15
US62/050,745 2014-09-15
PCT/US2015/050051 WO2016044189A1 (en) 2014-09-15 2015-09-14 Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists

Publications (1)

Publication Number Publication Date
CN106687135A true CN106687135A (zh) 2017-05-17

Family

ID=54325043

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580048941.5A Pending CN106687135A (zh) 2014-09-15 2015-09-14 使用pd‑1轴结合拮抗剂和il‑17结合拮抗剂治疗癌症的方法

Country Status (5)

Country Link
US (3) US20170274073A1 (https=)
EP (1) EP3194440A1 (https=)
JP (2) JP2017534577A (https=)
CN (1) CN106687135A (https=)
WO (1) WO2016044189A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110621697A (zh) * 2017-05-25 2019-12-27 百时美施贵宝公司 拮抗性cd40单克隆抗体及其用途
WO2020057225A1 (zh) * 2018-09-17 2020-03-26 苏州泓迅生物科技股份有限公司 一种抗pd-l1抗体及其制备方法和应用

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
KR20180097615A (ko) 2016-01-08 2018-08-31 에프. 호프만-라 로슈 아게 Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
WO2017136497A1 (en) * 2016-02-03 2017-08-10 The Cleveland Clinic Foundation Detection and treatment of il-17 and il-13 related conditions
AU2017248061A1 (en) * 2016-04-08 2018-10-25 Centre Antoine Lacassagne Methods and kits for predicting the sensitivity of a subject suffering of renal cancer to cancer treatment
WO2018027524A1 (en) * 2016-08-09 2018-02-15 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibody formulation
US20190270802A1 (en) * 2016-10-21 2019-09-05 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and an il-27 antagonist
KR20190139216A (ko) 2017-04-28 2019-12-17 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법
US11299540B2 (en) 2017-06-18 2022-04-12 Kindred Biosciences, Inc. IL17A antibodies and antagonists for veterinary use
US12297272B2 (en) 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
EP3483180A1 (en) * 2017-11-14 2019-05-15 Affilogic Multi specific molecules
CA3084370A1 (en) * 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
US12109249B2 (en) 2018-01-30 2024-10-08 University Of Louisville Research Foundation Compositions and methods for treating inflammation and cancer
JP2021524744A (ja) * 2018-05-21 2021-09-16 ナノストリング テクノロジーズ，インコーポレイティド 分子遺伝子シグネチャーとその使用方法
CN110563842B (zh) * 2018-06-06 2022-07-29 浙江博锐生物制药有限公司 针对程序性死亡配体(pd-l1)的抗体及其应用
KR102091637B1 (ko) * 2018-07-10 2020-03-20 연세대학교 산학협력단 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
WO2020150208A1 (en) * 2019-01-14 2020-07-23 Board Of Regents, The University Of Texas System Compositions and methods for treating cancer using il-17 signaling inhibitors and immune checkpoint inhibitors
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
PT3946377T (pt) * 2019-04-03 2026-03-09 Univ Montpellier Terapias de combinação baseadas em inibidores da pd1 e il-17b
WO2020218322A1 (ja) * 2019-04-23 2020-10-29 国立大学法人東北大学 血中ケモカインを用いた免疫チェックポイント阻害薬の治療効果予測
WO2021202959A1 (en) * 2020-04-03 2021-10-07 Genentech, Inc. Therapeutic and diagnostic methods for cancer
US20230167497A1 (en) * 2020-04-30 2023-06-01 Xiaohua Xue Methods of identifying modulators of the il-17 pathway
CN119497573A (zh) * 2022-07-29 2025-02-21 金凤实验室 一种表达il-8的非人哺乳动物模型及其用途
WO2025003035A1 (en) * 2023-06-30 2025-01-02 Universitätsklinikum Essen Il-17 based therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102177179A (zh) * 2008-08-08 2011-09-07 葛兰素集团有限公司 自身免疫性和炎性疾病的治疗
WO2011141823A3 (en) * 2010-05-14 2012-01-05 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
WO2013019906A1 (en) * 2011-08-01 2013-02-07 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
CN103890008A (zh) * 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 在顽固性肿瘤中抑制血管发生
WO2014109617A1 (ko) * 2013-01-14 2014-07-17 가톨릭대학교 산학협력단 HtrA2 단백질을 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 조성물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102177179A (zh) * 2008-08-08 2011-09-07 葛兰素集团有限公司 自身免疫性和炎性疾病的治疗
WO2011141823A3 (en) * 2010-05-14 2012-01-05 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
WO2013019906A1 (en) * 2011-08-01 2013-02-07 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
CN103842030A (zh) * 2011-08-01 2014-06-04 霍夫曼-拉罗奇有限公司 使用pd-1轴结合拮抗剂和mek抑制剂治疗癌症的方法
CN103890008A (zh) * 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 在顽固性肿瘤中抑制血管发生
WO2014109617A1 (ko) * 2013-01-14 2014-07-17 가톨릭대학교 산학협력단 HtrA2 단백질을 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 조성물

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B.ELEWSKI ET AL.: "A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis", 《BRITISH JOURNAL OF DERMATOLOGY》 *
GOPAL MURUGAIYAN ET AL: "Protumor vs antitumor functions of IL-17", 《THE JOURNAL OF IMMUNOLOGY》 *
JÉRÉMY BASTID ET AL.: "Lymphocyte-derived interleukin-17A adds another brick in the wall of inflammation-induced breast carcinogenesis", 《ONCOIMMUNOLOGY》 *
S.MUENST ET AL: "Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer", 《BREAST CANCER RESEARCH AND TREATMENT》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110621697A (zh) * 2017-05-25 2019-12-27 百时美施贵宝公司 拮抗性cd40单克隆抗体及其用途
CN110621697B (zh) * 2017-05-25 2023-06-27 百时美施贵宝公司 拮抗性cd40单克隆抗体及其用途
WO2020057225A1 (zh) * 2018-09-17 2020-03-26 苏州泓迅生物科技股份有限公司 一种抗pd-l1抗体及其制备方法和应用
US12522662B2 (en) 2018-09-17 2026-01-13 Synbio Technologies Llc Anti-PD-L1 antibody, and preparation method therefor and application thereof

Also Published As

Publication number Publication date
WO2016044189A9 (en) 2017-05-11
JP2017534577A (ja) 2017-11-24
US20170274073A1 (en) 2017-09-28
WO2016044189A8 (en) 2017-03-23
US20200405855A1 (en) 2020-12-31
EP3194440A1 (en) 2017-07-26
US20200155676A1 (en) 2020-05-21
JP2021001176A (ja) 2021-01-07
WO2016044189A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
US20200405855A1 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
AU2021202413B9 (en) Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
JP6312659B2 (ja) Ｐｄ−１系結合アンタゴニスト及びｖｅｇｆアンタゴニストを用いた癌の治療方法
KR102500659B1 (ko) 암에 대한 치료 및 진단 방법
ES2850428T3 (es) Procedimientos de monitorización y tratamiento del cáncer
CN107109484B (zh) 用于ox40激动剂治疗的功效预测和评估的方法和生物标志物
KR20170096112A (ko) Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
CN107750164A (zh) 使用抗ox40抗体和pd‑1轴结合拮抗剂治疗癌症的方法
CN106102774A (zh) 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
CN106796235A (zh) 用于检测t细胞免疫子集的测定法及其使用方法
JP2019515670A (ja) がんをモニタリングし治療するための方法
ES2955032T3 (es) Métodos de diagnóstico para el cáncer de mama triple negativo
KR20230024368A (ko) 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
US20240060135A1 (en) Therapeutic and diagnostic methods for cancer
KR20220070237A (ko) 항-tigit 및 항-pd-l1 길항제 항체를 이용한 치료를 위한 투약
KR20230025691A (ko) 삼중 음성 유방암을 치료하기 위한 방법과 조성물
HK1237659A1 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
RU2825390C2 (ru) Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit
HK40002464A (en) Methods for monitoring and treating cancer
HK40002465A (en) Methods for monitoring and treating cancer
HK1238715B (zh) 用於检测t细胞免疫子集的测定法及其使用方法
TW202604570A (zh) 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1237659

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170517

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1237659

Country of ref document: HK